Vuse Vibe and Vuse Ciro receive US FDA Marketing Authorization

•  FDA’s Marketing Granted Orders (MGOs) confirm that marketing of Vuse Vibe and Ciro products, in original flavour, is appropriate for the protection of public health
•  Vuse Vibe and Ciro add to PMTA orders granted in October 2021 for Vuse Solo original flavour
•  BAT’s multi-category approach and journey towards delivering A Better Tomorrow™ is supported by these FDA MGOs
•  These authorisations represent the broadest portfolio of Market Authorizations provided to any company in the U.S
   

Today, BAT’s U.S. indirect subsidiary, R. J. Reynolds Vapor Company, received Marketing Authorization from the U.S. Food and Drug Administration (FDA) for certain Vuse Ciro and Vuse Vibe products that will allow them to remain on the market in the United States.  This news builds on the prior Marketing Authorizations granted by FDA in October 2021 for Vuse Solo products in original flavour.

The FDA issued Marketing Authorization for Vuse Vibe and Vuse Ciro original flavours.  Menthol remains under review and can remain on market pending a decision from the agency.  FDA issued a denial for the applications of other flavours.  Those flavoured vapour products, in accordance with prior-issued FDA industry guidance, are not currently marketed or sold in the U.S.  We are reviewing FDA’s decision on those applications to determine next steps. 

Dr. David O’Reilly, Director of Scientific Research, BAT, said: “These authorisations represent the broadest portfolio of Market Authorizations provided to any company in the U.S for Premarket Tobacco Product Applications (PMTA).  Continued focus on science and innovation has supported the robust submissions, which have enabled FDA to evaluate and authorise the marketing of these products. 

“We are proud of the work undertaken by the team to achieve this significant regulatory milestone and are confident in the quality of our applications.

“Our corporate purpose is clear: to build A Better Tomorrow by reducing the health impact of our business.  We are committed to Tobacco Harm Reduction and believe our portfolio of scientifically substantiated reduced-risk products*† can play a critical role in delivering it.  As part of this commitment, we will continue to work with FDA to support access and choice for adult consumers.”

The PMTAs submitted by R. J. Reynolds Vapour Company in 2020 included rigorous scientific studies for Vuse Vibe and Vuse Ciro.  These build on the science submitted in the U.S. business’s first PMTA submission to the FDA with respect to Vuse Solo, which was granted Marketing Authorization in October 2021 for its original flavour.  The science in these applications demonstrates that the continued marketing of the Vuse Vibe and Vuse Ciro products is appropriate for the protection of the public health. 

Vuse Alto remains under review and will continue to be available for adult nicotine consumers. The Vuse Alto PMTA was submitted nearly a year after Vuse Solo, and five months after Vuse Vibe and Ciro, and those applications share foundational science.